**Abstract.** Background/Aim: Cardiovascular diseases are a leading cause of mortality and morbidity worldwide. Polymorphisms in the **SCARB1** gene are known to be related to plasma lipids. Patients and Methods: Real time-polymerase chain reaction (RT-PCR) was used for identification of **SCARB1** polymorphisms and the Lipoprint Quantimetrix System was employed in identification of HDL subfractions. Results: According to allelic distribution, in both groups **SCARB1** AA genotype led to a two-fold decrease in the risk of developing cardiovascular disease (p=0.04), while the GA genotype increased the risk two-fold (p=0.03). According to the HDL subfraction analysis results, the AA genotype had higher levels of big-sized HDL subfraction (p=0.02). Conclusion: The **SCARB1**AA genotype decreased cardiovascular risk and carrying GA genotype and G allele increased the risk of CAD. AA genotype carriers had higher levels of big-sized HDL subfraction.

Cardiovascular diseases are a leading cause of mortality and morbidity worldwide (1). In cardiovascular diseases, mortality commonly occurs because of coronary artery disease (CAD) related to the damage of heart tissue (2). Considering HDL subfractions as being more important than HDL cholesterol, polyacrylamide gel electrophoresis was used and HDL was classified into 3 subclasses, big-sized HDL, intermediate-sized HDL, small-sized HDL; big sized and intermediate sized HDL subfractions were accepted as anti-atherogenic and the small sized HDL subfraction group was accepted as atherogenic (3, 4). Some researches have suggested that there is a relationship between the variations of **SCARB1** gene and serum lipid profile (5, 6). In our study, we aimed to investigate the relationships between HDL subfractions and 2 variations of the **SCARB1** gene in CAD cases.

**Materials and Methods**

Blood samples of patient (n=52) and control (n=58) groups were obtained from Marmara University, Department of Cardiovascular Surgery. Ethical Committee of Yeditepe University approved the study (2016-KAERK-1242, Decision No: 646, date: 29.06.2016). Control group subjects were chosen to have no risk of cardiovascular disease. Venous blood was obtained from each subject and conserved at +4˚ until DNA isolation. Isolation of DNA from blood samples was performed using the Invitrogen iPrep Purification Instrument and the iPrep PureLink gDNA Blood Kits (Invitrogen, Life Technologies, Carlsbad, CA, USA) according to the manufacture’s protocol. To determine the DNA concentration, NanoDrop 2000 device (Thermo Scientific, Waltham, MA, USA) was used.

**Genotyping.** Genotyping of samples was carried out by Applied Biosystems Fast Real-Time polymerase chain reaction (RT-PCR) instrument and TaqMan Reagents primer-probe sets (Applied Biosystems, Foster City, CA, USA), specifically designed for **SCARB1** gene rs 10846744 and **SCARB1** rs 5888 polymorphisms. PCR reaction mixture contained 10 μl X Genotyping Master Mix, 0.5 μl 40X TaqMan Genotyping Assay (TaqMan Reagents; Applied Biosystems, Foster City, CA, USA), 8.5 μl PCR grade water and 1 μl of sample DNA. PCR conditions were 10 min of holding stage at 95˚C and 40 cycles of 15 sec denaturation at 92˚C and 60 sec of annealing/extension at 60˚C as recommended by the supplier. Allelic discrimination was done using the software of 7500 Fast real-time PCR instrument.

**Analysis of HDL subfractions.** Analysis of HDL subfractions were performed by the Quantimetrix Lipoprint HDL System. Lipophilic dyes bind comparatively to the relative amount of cholesterol in each lipoprotein. In the first stage of electrophoresis, lipoprotein particles were condensed in a sharp band upon loading in the stacking gel. Lipoprotein particles then moved through the separating gel matrix and resolved according to the particle sizes.
The demographic characteristics of CAD and control groups were given in Table I. By comparison with diabetes diagnosis in both groups, 36.5% of patient and 19.0% of control groups had a diabetes diagnosis. The results demonstrated that the diabetes risk was 2.46 fold higher for CAD ($x^2$: 4.269, $p=0.03$, OR=2.46, 95%CI=1.035-5.847). Furthermore, there was a significantly higher number of hypertensive individuals in the patient group and hypertension risk was increased 2.51 fold for CAD ($x^2$: 4.166, $p=0.04$, OR=2.51, 95%CI=1.023-6.183).

HDL subfractions of patient and control groups are shown comparatively in Table IV. The mean of big sized HDL levels was 8.50±4.00 mg/dl, whereas in the patient group the mean of the small sized HDL levels was 6.63±3.04 mg/dl. Between the groups, small sized HDL was significantly different.

The genotypic and allelic frequencies of SCARB1 rs10846744 polymorphism are given in Table III. The frequencies of CC, CG, GG were 5.8%, 34.6%, 38.6% in the patient group, whereas in the control group they were 6.9%, 36.2%, 56.9%. When the allelic frequencies were examined; the frequencies of C and G alleles were 21.81% and 72.72% in the patient group respectively. The frequencies of C and G alleles were 26.36% and 79.09% in the control group. There were no significant differences in the genotypic and allelic frequencies between both groups.

The genotypic and allelic frequencies of SCARB1 gene rs5888 polymorphism are shown in Table III. In comparison between patient and control groups; the frequencies of AA, GA, GG were 17.30%, 57.7%, 25.0% in the patient group, and 34.5%, 37.9% and 27.6% in the control group respectively. Carriers of the AA genotype were significantly higher in the control group and the risk was 2.51 fold reduced in CAD ($x^2$: 4.16, $p=0.04$, OR=0.398, 95%CI=0.162-0.978). Analyses also showed that the GA genotype carriers had a 2.23-fold increased risk for CAD ($x^2$: 4.296, $p=0.03$, OR=2.23, 95%CI=1.039-4.791). Examining the allelic frequencies demonstrated that the frequencies of A and G alleles were 43.63% and 50.90% in the patient group, and the frequencies of the A allele and G allele were 56.36%, 49.09% in the control group. Carrying the G allele was observed to increase the risk of CAD ($x^2$: 4.166, $p=0.04$, OR=2.515, 95%CI=1.023-6.183).

Distribution of HDL subfractions and genotypic distribution of the SCARB1 G>A polymorphism are shown comparatively in Table IV. The mean of big sized HDL level in patients with the AA genotype was 14.48±9.01 mg/dl, 11.94±5.01 mg/dl with the GA genotype, and 10.30±3.58 mg/dl with the GG genotype. Big sized HDL in patients with the AA genotype was significantly higher than with the other genotypes.

**Results**

The demographic characteristics of CAD and control groups were given in Table I. By comparison with diabetes diagnosis in both groups, 36.5% of patient and 19.0% of control groups had a diabetes diagnosis. The results demonstrated that the diabetes risk was 2.46 fold higher for CAD ($x^2$: 4.269, $p=0.03$, OR=2.46, 95%CI=1.035-5.847). Furthermore, there was a significantly higher number of hypertensive individuals in the patient group and hypertension risk was increased 2.51 fold for CAD ($x^2$: 4.166, $p=0.04$, OR=2.51, 95%CI=1.023-6.183).

HDL subfractions of patient and control groups are shown comparatively in Table IV. The mean of big sized HDL levels was 8.50±4.00 mg/dl, whereas in the patient group the mean of the small sized HDL levels was 6.63±3.04 mg/dl. Between the groups, small sized HDL was significantly different.

The genotypic and allelic frequencies of SCARB1 rs10846744 polymorphism are given in Table III. The frequencies of CC, CG, GG were 5.8%, 34.6%, 38.6% in the patient group, whereas in the control group they were 6.9%, 36.2%, 56.9%. When the allelic frequencies were examined; the frequencies of C and G alleles were 21.81% and 72.72% in the patient group respectively. The frequencies of C and G alleles were 26.36% and 79.09% in the control group. There were no significant differences in the genotypic and allelic frequencies between both groups.

The genotypic and allelic frequencies of SCARB1 gene rs5888 polymorphism are shown in Table III. In comparison between patient and control groups; the frequencies of AA, GA, GG were 17.30%, 57.7%, 25.0% in the patient group, and 34.5%, 37.9% and 27.6% in the control group respectively. Carriers of the AA genotype were significantly higher in the control group and the risk was 2.51 fold reduced in CAD ($x^2$: 4.16, $p=0.04$, OR=0.398, 95%CI=0.162-0.978). Analyses also showed that the GA genotype carriers had a 2.23-fold increased risk for CAD ($x^2$: 4.296, $p=0.03$, OR=2.23, 95%CI=1.039-4.791). Examining the allelic frequencies demonstrated that the frequencies of A and G alleles were 43.63% and 50.90% in the patient group, and the frequencies of the A allele and G allele were 56.36%, 49.09% in the control group. Carrying the G allele was observed to increase the risk of CAD ($x^2$: 4.166, $p=0.04$, OR=2.515, 95%CI=1.023-6.183).

Distribution of HDL subfractions and genotypic distribution of the SCARB1 G>A polymorphism are shown comparatively in Table IV. The mean of big sized HDL level in patients with the AA genotype was 14.48±9.01 mg/dl, 11.94±5.01 mg/dl with the GA genotype, and 10.30±3.58 mg/dl with the GG genotype. Big sized HDL in patients with the AA genotype was significantly higher than with the other genotypes.

**Discussion**

Recent studies, have suggested that total plasma lipid levels are not enough as determining factors for CAD and emphasized that lipoprotein subfractions should also be studied. Nearly half the individuals with CAD had normal total cholesterol levels and therefore it was thought that the...
Hypertension is a predisposing factor for atherosclerosis. Using the Lipoprint System, based on the polyacrylamide gel electrophoresis principle, the HDL subfractions were classified as big-sized HDL, intermediate-sized HDL and small-sized HDL. It has been suggested that big-sized HDL and intermediate-sized HDL have protective properties and small HDL had atherogenic properties.

Hamidreze et al. (2016) investigated the relationship between premature CAD and SCARB1 C>T variation at cDNA position 1050 base position on exon 8 (rs 5888) and their results showed similarities with our study. They found that the T allele was 1.3 fold increased compared to the C allele in CAD cases. TT genotype increased the risk of CAD 1.7 times. TT genotype increased the risk of CAD in women more than in men (8). Dong-Fen-Wu et al. investigated the effects of SCARB1 C>T polymorphism in CAD, but opposite to our findings, they found that the TT genotype was higher in the patient group and revealed that the TT genotype increased the risk of CAD. TT genotype carriers had lower HDL levels (9). Jihene et al. indicated that in the control group, TT genotype carriers had higher HDL levels and a decreased risk of CAD (10).

Hypertension is a predisposing factor for atherosclerosis by causing a continuous injury in the endothelium. Advanced atherosclerosis contributes to plaque growth. It has been observed that hypertension increases stroke risk by 2 times and heart attack risk by 3 times compared to cases with a normal blood pressure. Yan et al. investigated the relationship between hypertension and HDL subfractions in a study of 953 hypertensive patients. It was determined that the large HDL subfraction levels in hypertensive patients was lower and the small HDL subfraction of the same patients was higher compared to their equivalents. While the big-sized HDL subfractions result in a low risk of hypertension, small HDL subfractions increase hypertension risk. Big sized HDL levels have not been associated with any predisposition to CAD in patients with hypertension. Besides, it was observed that small-sized HDL subfractions were lower in patients whose blood pressure was successfully controlled (11).

Rui-Xia et al. studied the relationships between HDL subfractions and CAD and observed that coronary artery patients had decreased levels of HDL-cholesterol, especially the big-sized HDL. In our study, we found that small-sized HDL level was higher in the control group. And there were no significant differences of intermediate HDL between the two groups. We also observed that there was an inverse relationship between the level of big-sized HDL subfractions and CAD. The risk of development of CAD increases with

### Table III. rs5888 and rs10846744 genotypic and allelic frequencies in patients with CAD and the control group.

<table>
<thead>
<tr>
<th>Genotype Scarb1 G&gt;A</th>
<th>Control (n=58)</th>
<th>Patient (n=52)</th>
<th>p-Value</th>
<th>Odds ratio (OR)</th>
<th>95% confidence interval (CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>AA</td>
<td>34.5% (20)</td>
<td>17.3% (9)</td>
<td>0.04*</td>
<td>0.398</td>
<td>0.162-0.978</td>
</tr>
<tr>
<td>GA</td>
<td>37.9% (22)</td>
<td>57.7% (30)</td>
<td>0.03*</td>
<td>2.231</td>
<td>1.039-4.791</td>
</tr>
<tr>
<td>GG</td>
<td>27.6% (16)</td>
<td>25.0% (13)</td>
<td>0.75</td>
<td>0.875</td>
<td>0.373-2.051</td>
</tr>
<tr>
<td>A</td>
<td>56.36% (62)</td>
<td>43.63% (48)</td>
<td>0.75</td>
<td>1.143</td>
<td>0.488-2.679</td>
</tr>
<tr>
<td>G</td>
<td>49.09% (54)</td>
<td>50.90% (56)</td>
<td>0.04*</td>
<td>2.515</td>
<td>1.023-6.183</td>
</tr>
</tbody>
</table>

### Table IV. Distribution of HDL subfractions dependent genotype in the SCARB1 G>A polymorphism.

<table>
<thead>
<tr>
<th>Subfraction</th>
<th>AA</th>
<th>GA</th>
<th>GG</th>
<th>p-Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Big Sized HDL</td>
<td>14.48±9.01</td>
<td>11.94±5.01</td>
<td>10.30±3.58</td>
<td>0.02*</td>
</tr>
<tr>
<td>Intermediate HDL</td>
<td>21.97±5.77</td>
<td>21.46±4.10</td>
<td>20.26±5.18</td>
<td>0.40</td>
</tr>
<tr>
<td>Small Sized HDL</td>
<td>8.31±4.54</td>
<td>7.23±3.25</td>
<td>7.37±3.28</td>
<td>0.19</td>
</tr>
</tbody>
</table>

n: Number of individuals; *statistically significant difference.
the level of small HDL subfractions; in the patients with a high ratio of small HDL subfractions, there is a risk of CAD development (12).

Georg et al. found an inverse relationship between big sized HDL levels and the patients with myocardial infarction and also there was a direct relationship between intermediate-sized and small-sized HDL levels and myocardial infarctions (13).

Rui-Xia et al. (2015) found that coronary artery patients had lower levels of big-sized HDL and concluded that small-sized HDL levels were related to CAD (14). Jian-Jun et al. (2016) observed that big-sized HDL levels were inversely correlated with the risk of cardiovascular diseases (15).

In another study by Rui-Xia et al. it was found that big- and intermediate-sized HDL subfractions levels were lower in patients compared to healthy people. Intermediate- and small-sized HDL were found to be associated with the risk of CAD development (16).

Conclusion

In the single nucleotide polymorphism (SNP) of rs5888, a “G” to “A” substitution at amino acid 350 in exon 8 of the SCARB1 gene, the AA genotype decreases cardiovascular risk two times \((p=0.04)\), and the GA genotype increases two times the same risk \((p=0.03)\). According to the HDL subfraction analysis results, AA genotype carriers had higher levels of big-sized HDL subfractions that are known to be antiatherogenic \((p=0.02)\).

Conflicts of Interest

The Authors declare no conflicts of interest in regard to this study.

References


Received May 30, 2017
Revised June 22, 2017
Accepted June 23, 2017